Axplora invests €8 million in Le Mans to further expand its capacity for antibody drug conjugate manufacturing:
Axplora partners with Pharma companies and Biotechs to deliver innovative cancer treatments for thousands of patients worldwide
With over 15 years experience in the synthesis and purification of commercial antibody drug conjugates, Le Mans (France) delivers high quality and security of supply for customers
Optimizing the biomedicines production chain has been recognized as a key priority by the French government and this project is proud to be part of the France 2030 program
Axplora, a leading partner to Pharma companies and Biotechs for complex APIs, is pleased to announce a €8 million investment to expand capacity for antibody drug conjugate payload manufacturing at its Le Mans site (France), to deliver life-changing cancer treatments for patients.
This investment creates a new production suite for antibody drug conjugate payload manufacturing, to enable innovative pharmaceutical partners to develop the next generation of targeted therapies in oncology. This new suite will allow us to produce various payloads at kilogram scale to secure the supply of API for our customers. It has been designed to operate over a wide range of process conditions with best-in-class process equipment and containment technology.
In addition, at least 15 new positions will be created to support the site in this ambitious project that will help improve patients’ lives.
“This increased capacity is the result of our long-term strategy of growing in a sustainable manner, with the commitment to provide more efficient and optimized manufacturing processes to secure the supply chain of our customers”, says Rachel De Luca, Site Director in Le Mans. “We are proud to develop tomorrow’s anticancer drugs to treat patients and confident that this investment will open up new opportunities to fight against cancer together with agility and reliability”.
“We welcome the support of the French government which allow us to accelerate our development and broaden our offering to our customers. », adds Philippe Gaucher, Technical Director. « We are pleased to be part of the National program to encourage the development of biopharmaceuticals – France 2030 – and to strengthen our position to develop and produce innovative anticancer drugs in France. »
